STOCK TITAN

Reviva Pharma Holdings (RVPH) Financials

RVPH OTC
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$11.3M n/m YoY
EPS (Diluted) Not reported for the trailing 12 months
Operating Cash Flow -$13.9M n/m YoY
Market Cap $3.9M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.3x on $13.1M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RVPH SEC filings page.

This page shows Reviva Pharma Holdings Inc (RVPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RVPH FY2025

Reviva’s FY2025 figures describe a research-led business: a net loss of $19.9M and operating cash outflow of $24.6M.

Cash conversion is weaker than the reported loss: FY2025 operating cash outflow exceeded the net loss, indicating that reported expenses understates the cash absorbed by operations. The same gap appeared in FY2024, when the company reported a net loss of $29.9M against operating cash outflow of $33.5M, making this a recurring operating pattern rather than a one-year mismatch.

Lower operating losses came alongside lower development spending, not visible revenue scale. Research and development fell to $11.7M in FY2025 from $22.9M in FY2024, while operating loss narrowed to $20.2M from $30.8M; the improvement therefore coincided with reduced research investment.

The balance sheet materially reset in FY2025: liabilities fell to $7.3M from $14.7M, while equity rose to $8.6M from just $813K. The current ratio also improved to 2.1x from 1.0x, indicating greater short-term asset coverage after the prior year’s balance-sheet compression.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Reviva Pharma Holdings Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

Reviva Pharma Holdings Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Reviva Pharma Holdings Inc reported a net loss of $19.9M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Reviva Pharma Holdings Inc reported an operating loss of $20.2M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$2.3M
YoYn/m
QoQn/m

Reviva Pharma Holdings Inc reported a net loss of $2.3M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$17.5M
YoY+32.4%
QoQ-12.2%
5Y CAGR-12.2%

Reviva Pharma Holdings Inc held $17.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
13M
QoQ0.0%

Reviva Pharma Holdings Inc had 13M shares outstanding in Q3 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-17.6%
YoY+70.6pp
QoQ-1.5pp

Reviva Pharma Holdings Inc's quarterly ROE was -17.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 70.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.5 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$1.2M
YoY-43.8%
QoQ-14.1%

Reviva Pharma Holdings Inc invested $1.2M in research and development in Q3 2026. This represents a decrease of 43.8% from the same quarter a year earlier. Against the prior quarter it is down 14.1%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

RVPH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RVPH quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$1.2M-43.8%$1.4M-62.6%$1.4M-65.1%$1.7M-62.8%$2.1M-68.9%$3.7M-33.3%$4.1M-28.9%$4.7M-42.3%
SG&A Expenses$1.2M-35.0%$1.2M-47.9%$1.8M-24.2%$1.8M+13.5%$1.9M+18.3%$2.3M-7.7%$2.4M+13.4%$1.6M+6.1%
Operating Income-$2.4Mn/m-$2.6Mn/m-$3.3Mn/m-$3.6Mn/m-$4.0Mn/m-$6.1Mn/m-$6.5Mn/m-$6.3Mn/m
Interest Expense$1K-54.9%$3K-38.8%$7K-42.7%N/A$3K-49.4%$5K-6.9%$12K+233.2%$5K
Income Tax$2K-31.9%$3K-66.9%$3K-35.8%$3K-39.1%$3Kn/m$8K+7.7%$5K-29.5%$5Kn/m
Net Income-$2.3Mn/m-$2.4Mn/m-$3.2Mn/m-$3.4Mn/m-$4.0Mn/m-$6.1Mn/m-$6.4Mn/m-$6.3Mn/m
EPS (Basic)-$0.17-$0.19-$0.46N/A-$1.09-$2.40-$2.61n/m-$3.00n/m

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, EPS (Diluted), Diluted Shares (Avg).

RVPH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RVPH quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$18.6M+29.5%$21.1M+81.7%$23.6M+232.9%$15.9M+2.7%$14.3M+87.8%$11.6M+44.5%$7.1M-47.6%$15.5M-34.6%
Current Assets$18.6M+37.3%$21.1M+95.5%$23.6M+276.5%$15.1M+2.9%$13.5M+98.4%$10.8M+49.5%$6.3M$14.7M-38.0%
Cash & Equivalents$17.5M+32.4%$19.9M+91.9%$22.2M+319.5%$14.4M+7.1%$13.2M+137.2%$10.4M+67.7%$5.3M-55.8%$13.5M-42.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$5.5M-44.0%$5.9M-50.9%$6.1M-47.0%$7.3M-50.5%$9.8M-44.5%$12.1M-14.2%$11.5M-22.3%$14.7M-18.3%
Current Liabilities$5.5M-43.7%$5.9M-50.9%$6.1M-46.8%$7.3M-50.2%$9.7M-44.5%$12.1M-13.4%$11.5M-20.6%$14.6M-15.0%
Non-Current Liabilities$0-100.0%$0-100.0%$0-100.0%$0-100.0%$45K-42.9%$17K-88.9%$28K-92.1%$89K-89.0%
Total Equity$13.1M+187.5%$15.2Mn/m$17.4Mn/m$8.6M+964.2%$4.5Mn/m-$459Kn/m-$4.5Mn/m$813K-85.8%
Retained Earnings-$192.1Mn/m-$189.8Mn/m-$187.3Mn/m-$184.1Mn/m-$180.8Mn/m-$176.8Mn/m-$170.7Mn/m-$164.3Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

RVPH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RVPH quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$2.2Mn/m-$2.1Mn/m-$3.8Mn/m-$5.8Mn/m-$5.6Mn/m-$5.0Mn/m-$8.2Mn/m-$9.1Mn/m
Stock-Based Compensation$171K-62.7%$215K-45.7%$584K-36.4%N/A$458K+31.7%$395K+10.1%$919K+149.0%N/A
Financing Cash Flow-$247K-102.9%-$185K-101.8%$11.6M+158787.8%$7.1M-58.6%$8.4M+132.2%$10.1M+276.3%$7K-97.8%$17.0M-37.6%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

RVPH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RVPH quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-17.6%+70.6pp-16.1%-18.3%-38.9%+731.4pp-88.1%N/AN/A-770.3%-606.7pp
Return on Assets-12.4%+15.6pp-11.6%+40.4pp-13.6%+77.3pp-21.1%+19.2pp-28.0%+81.7pp-52.0%+45.6pp-90.9%-35.8pp-40.4%-0.9pp
Current Ratio3.39+2.0x3.56+2.7x3.85+3.3x2.08+1.1x1.39+1.0x0.90+0.4x0.541.01-0.4x
Liabilities-to-Equity0.42-1.7x0.390.350.84-17.2x2.15N/AN/A18.08+14.9x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Reviva Pharma Holdings Inc RVPH FY2025 N/A -$19.9M N/A $3.9M —
OSR Health Inc OSRH FY2025 $2.9M -$18.0M N/A $4.2M —
America Great Health AAGH FY2025 $392K -$719K N/A $4.2M —
BioAtla Inc BCAB FY2025 N/A -$59.6M N/A $2.6M —
Oncotelic Therapeutcs Inc OTLC FY2025 N/A $249.3M N/A $5.9M —

Frequently Asked Questions

No, Reviva Pharma Holdings Inc (RVPH) reported a net loss of $11.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $19.9M.

Reviva Pharma Holdings Inc (RVPH) has a return on equity of -229.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Reviva Pharma Holdings Inc (RVPH) recorded an outflow of $24.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Reviva Pharma Holdings Inc (RVPH) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Reviva Pharma Holdings Inc (RVPH) invested $11.7M in research and development during fiscal year 2025.

Reviva Pharma Holdings Inc (RVPH) had 13M shares outstanding as of fiscal year 2025.

Reviva Pharma Holdings Inc (RVPH) had a current ratio of 2.08 as of fiscal year 2025, which is generally considered healthy.

Reviva Pharma Holdings Inc (RVPH) had a liabilities-to-equity ratio of 0.84 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Reviva Pharma Holdings Inc (RVPH) had a return on assets of -124.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Reviva Pharma Holdings Inc (RVPH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $3.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Reviva Pharma Holdings Inc (RVPH) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $3.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Reviva Pharma Holdings Inc (RVPH) held $14.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $24.6M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Reviva Pharma Holdings Inc (RVPH) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Reviva Pharma Holdings Inc (RVPH) reported a net loss of $19.9M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Reviva Pharma Holdings Inc (RVPH) reported an operating loss of $20.2M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top